Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.80 |
| ▸ | MAOB | P27338 | 11/20 | 0.80 |
| ▸ | DRD2 | P14416 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.70 |
| ▸ | HTR2C | P28335 | 2/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.70 |
| ▸ | HTR7 | P34969 | 2/20 | 0.70 |
| ▸ | DRD3 | P35462 | 2/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672507 | 0.90 | DRD2 (0.67) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL10571057 | 0.87 | DRD2 (0.75) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL23097595 | 0.86 | DRD2 (0.81) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL10571545 | 0.86 | MAOA (0.86) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL16559664 | 0.85 | MAOA (1.00) | MAOAMAOBDRD2 | |
| SCHEMBL23097720 | 0.84 | DRD2 (0.75) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL10571461 | 0.84 | DRD2 (0.66) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL23097641 | 0.84 | DRD2 (0.66) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL10571129 | 0.84 | DRD2 (0.68) | MAOAMAOBDRD2HTR1AHTR2A | |
| SCHEMBL11344730 | 0.84 | KCNH2 (0.69) | MAOAMAOBDRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609847-B2 | Dihydroquinolinone derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2393802-A1 | DIHYDROQUINOLINONE DERIVATIVES | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | PER2, CRY1, BACE1 | MAOA 230/4885MAOB 193/4885DRD2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.